U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C59H84N16O12.C2H4O2
Molecular Weight 1269.4502
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEUPROLIDE ACETATE

SMILES

CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=C3C=CC=C4)NC(=O)[C@H](CC5=CNC=N5)NC(=O)[C@@H]6CCC(=O)N6

InChI

InChIKey=RGLRXNKKBLIBQS-XNHQSDQCSA-N
InChI=1S/C59H84N16O12.C2H4O2/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40;1-2(3)4/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64);1H3,(H,3,4)/t40-,41-,42-,43+,44-,45-,46-,47-,48-;/m0./s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/ppa/leuprolide.html | http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020011s040lbl.pdf | http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019010s033,019732s031s035s036,020517s024s028s029lbl.pdf

Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH or LH-RH). The analog possesses greater potency than the natural hormone. It acts primarily on the anterior pituitary, inducing a transient early rise in gonadotrophin release. With continued use, leuprorelin causes pituitary desensitisation and/or down-regulation, leading to suppressed circulating levels of gonadotrophins and sex hormones. Leuprolide acetate used to treat a wide range of sex hormone-related disorders including advanced prostatic cancer, uterine leiomyomata (fibroids), endometriosis and precocious puberty.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
LUPRON

Approved Use

LEUPROLIDE ACETATE INJECTION is indicated in the palliative treatment of advanced prostatic cancer.

Launch Date

1985
Primary
LUPRON DEPOT

Approved Use

Endometriosis LUPRON DEPOT 3.75 mg is indicated for management of endometriosis, including pain relief and reduction of endometriotic lesions. LUPRON DEPOT monthly with norethindrone acetate 5 mg daily is also indicated for initial management of endometriosis and for management of recurrence of symptoms. (Refer also to norethindrone acetate prescribing information for WARNINGS, PRECAUTIONS, CONTRAINDICATIONS and ADVERSE REACTIONS associated with norethindrone acetate). Duration of initial treatment or retreatment should be limited to 6 months. Uterine Leiomyomata (Fibroids) LUPRON DEPOT 3.75 mg concomitantly with iron therapy is indicated for the preoperative hematologic improvement of patients with anemia caused by uterine leiomyomata. The clinician may wish to consider a one-month trial period on iron alone inasmuch as some of the patients will respond to iron alone. (See Table 1.) LUPRON may be added if the response to iron alone is considered inadequate. Recommended duration of therapy with LUPRON DEPOT 3.75 mg is up to three months. Experience with LUPRON DEPOT in females has been limited to women 18 years of age and older.

Launch Date

1995
Primary
LUPRON DEPOT

Approved Use

Endometriosis LUPRON DEPOT 3.75 mg is indicated for management of endometriosis, including pain relief and reduction of endometriotic lesions. LUPRON DEPOT monthly with norethindrone acetate 5 mg daily is also indicated for initial management of endometriosis and for management of recurrence of symptoms. (Refer also to norethindrone acetate prescribing information for WARNINGS, PRECAUTIONS, CONTRAINDICATIONS and ADVERSE REACTIONS associated with norethindrone acetate). Duration of initial treatment or retreatment should be limited to 6 months. Uterine Leiomyomata (Fibroids) LUPRON DEPOT 3.75 mg concomitantly with iron therapy is indicated for the preoperative hematologic improvement of patients with anemia caused by uterine leiomyomata. The clinician may wish to consider a one-month trial period on iron alone inasmuch as some of the patients will respond to iron alone. (See Table 1.) LUPRON may be added if the response to iron alone is considered inadequate. Recommended duration of therapy with LUPRON DEPOT 3.75 mg is up to three months. Experience with LUPRON DEPOT in females has been limited to women 18 years of age and older.

Launch Date

1995
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
32.48 ng/mL
11.25 mg single, subcutaneous
dose: 11.25 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
LEUPROLIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
426.2 ng × h/mL
11.25 mg single, subcutaneous
dose: 11.25 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
LEUPROLIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3 h
1 mg single, intravenous
dose: 1 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LEUPROLIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
54%
1 mg single, intravenous
dose: 1 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LEUPROLIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Other AEs: Asthenia, General body pain...
Other AEs:
Asthenia (6 patients)
General body pain (16 patients)
Headache (5 patients)
Injection site reaction (4 patients)
Hot flashes (23 patients)
Gastrointestinal disorder (NOS) (5 patients)
Dehydration (4 patients)
Edema (4 patients)
Disorder joint (8 patients)
Myalgia (4 patients)
Vertigo (3 patients)
Neuromuscular disorders (3 patients)
Paresthesia (4 patients)
Skin reaction (6 patients)
Urinary tract disorder NOS (5 patients)
Sources:
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
n = 56
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 56
Sources:
Other AEs: General body pain, Hot flashes...
Other AEs:
General body pain (13 patients)
Hot flashes (32 patients)
Gastrointestinal disorder (NOS) (8 patients)
Edema (8 patients)
Libido decreased (3 patients)
Disorder urinary tract (7 patients)
Impotence (3 patients)
Atrophy testicular (3 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
General body pain 16 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Hot flashes 23 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Neuromuscular disorders 3 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Vertigo 3 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Dehydration 4 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Edema 4 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Injection site reaction 4 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Myalgia 4 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Paresthesia 4 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Gastrointestinal disorder (NOS) 5 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Headache 5 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Urinary tract disorder NOS 5 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Asthenia 6 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Skin reaction 6 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Disorder joint 8 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
General body pain 13 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
n = 56
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 56
Sources:
Atrophy testicular 3 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
n = 56
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 56
Sources:
Impotence 3 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
n = 56
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 56
Sources:
Libido decreased 3 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
n = 56
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 56
Sources:
Hot flashes 32 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
n = 56
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 56
Sources:
Disorder urinary tract 7 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
n = 56
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 56
Sources:
Edema 8 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
n = 56
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 56
Sources:
Gastrointestinal disorder (NOS) 8 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
n = 56
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 56
Sources:
PubMed

PubMed

TitleDatePubMed
Stable transfection of GH3 cells with rat gonadotropin-releasing hormone receptor complementary deoxyribonucleic acid results in expression of a receptor coupled to cyclic adenosine 3',5'-monophosphate-dependent prolactin release via a G-protein.
1994 Jul
[Effects of androgen regulation system on bladder carcinogenesis in male mice].
1995 Nov
Pituitary apoplexy after leuprolide administration for carcinoma of the prostate.
1996 Jan
"Add-back" estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri.
1996 Jul
Anxiety and mood disorders associated with gonadotropin-releasing hormone agonist therapy.
1997
Pituitary apoplexy of a gonadotroph adenoma following gonadotrophin releasing hormone agonist therapy for prostatic cancer.
1997 Oct
Steroidal 'add-back' therapy in patients treated with GnRH agonists.
1998
Sertraline in the treatment of depression associated with gonadotropin-releasing hormone agonist therapy.
1998 Mar 15
Lupron-induced mania.
1999 Jan 15
Macrophage Fcgamma receptors expression is altered by treatment with dopaminergic drugs.
1999 Mar
Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial.
2002 Sep
Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.
2003 Mar-Apr
Pituitary apoplexy after leuprolide.
2006
Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I.
2007 Jan
[Ischemic stroke associated with LH-RH analogue (leuprorelin) administration in a young woman].
2007 May
A possible participation of gonadotropin-releasing hormone in the neuroleptic and cataleptic effect of haloperidol.
2009 Jun
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Patents

Sample Use Guides

In Vivo Use Guide
Dosing: Adult Prostate cancer, advanced: Note: Treatment is usually continued after development of metastatic (castration-resistant) disease. IM: Lupron Depot 7.5 mg (monthly): 7.5 mg every month or Lupron Depot 22.5 mg (3 month): 22.5 mg every 12 weeks or Lupron Depot 30 mg (4 month): 30 mg every 16 weeks or Lupron Depot 45 mg (6 month): 45 mg every 24 weeks SubQ: Eligard: 7.5 mg monthly or 22.5 mg every 3 months or 30 mg every 4 months or 45 mg every 6 months Leuprolide acetate 5 mg/mL solution: 1 mg daily Endometriosis: IM: Initial therapy may be with leuprolide alone or in combination with norethindrone; if re-treatment for an additional 6 months is necessary, concomitant norethindrone should be used. Re-treatment is not recommended for longer than one additional 6-month course. Lupron Depot: 3.75 mg every month for up to 6 months or Lupron Depot-3 month: 11.25 mg every 3 months for up to 2 doses (6 months total duration of treatment) Uterine leiomyomata (fibroids): IM (in combination with iron): Lupron Depot: 3.75 mg every month for up to 3 months or Lupron Depot-3 month: 11.25 mg as a single injection Breast cancer, premenopausal ovarian supression (off-label use): IM: Lupron Depot: 3.75 mg every 28 days for up to 24 months (Boccardo 1999) or Lupron Depot-3 month: 11.25 mg every 3 months for up to 24 months (Boccardo 1999; Schmid 2007) Treatment of paraphilia/hypersexuality (off-label use; Guay 2009; Reilly 2000): Males: IM: Note: May cause an initial increase in androgen concentrations which may be treated with an antiandrogen (eg, flutamide, cyproterone) for 1 to 2 months (Guay 2009). Avoid use in patients with osteoporosis or active pituitary pathology. SubQ: Test dose: 1 mg (observe for hypersensitivity) Depot IM: 3.75 to 7.5 mg monthly Dosing: Geriatric Refer to adult dosing. Dosing: Pediatric Precocious puberty (consider discontinuing by age 11 for females and by age 12 for males): IM: Lupron Depot-Ped (monthly): ≤25 kg: 7.5 mg every month >25 to 37.5 kg: 11.25 mg every month >37.5 kg: 15 mg every month Titrate dose upward in increments of 3.75 mg every 4 weeks if down-regulation is not achieved. Lupron Depot-Ped (3 month): 11.25 mg or 30 mg every 12 weeks SubQ (leuprolide acetate 5 mg/mL solution): Initial: 50 mcg/kg/day; titrate dose upward by 10 mcg/kg/day if down-regulation is not achieved. Note: Higher mg/kg doses may be required in younger children.
Route of Administration: Other
In primary cell cultures from human prostate carcinoma leuprolide (from 5-20 ng/mL) showed a significant reduction in cell growth rate and an increase in DNA-fragmented cell number.
Name Type Language
LEUPROLIDE ACETATE
ORANGE BOOK   USAN   USP   USP-RS   VANDF  
USAN  
Official Name English
5-OXO-L-PROLYL-L-HISTIDYL-L-TRYPTOPHYL-L-SERYL-L-TRYOSYL-D-LEUCYL-L-LEUCYL-L-ARGINYL-N-ETHYL-L-PROLINAMIDE ACETATE (SALT)
Systematic Name English
LUCRIN
Brand Name English
LEUPROLIDE MONOACETATE [MI]
Common Name English
LEUPROLIDE ACETATE [ORANGE BOOK]
Common Name English
TAP-144
Code English
TAP-144-SR
Common Name English
PGLU-HIS-TRP-SER-TYR-D-LEU-LEU-ARG-PRO-NHC2H5 ACETATE SALT
Systematic Name English
LEUPORELIN ACETATE
Common Name English
LEUPROLIDE ACETATE [VANDF]
Common Name English
LEUPRORELIN ACETATE
MART.   WHO-DD  
Common Name English
ABBOTT-43818
Code English
1-9-LUTEINIZING HORMONE-RELEASING FACTOR (SWINE), 6-D-LEUCINE-9-(N-ETHYL-L-PROLINAMIDE)-, ACETATE (1:1)
Systematic Name English
LEUPROLIDE ACETATE [USAN]
Common Name English
A-43818
Code English
LUPRON DEPOT
Brand Name English
LUPANETA
Common Name English
CARCINIL
Brand Name English
LUPRON
Brand Name English
Leuprorelin acetate [WHO-DD]
Common Name English
VIADUR
Brand Name English
TRENANTONE
Brand Name English
LEUPRORELIN ACETATE [JAN]
Common Name English
LUTRATE DEPOT
Brand Name English
LEUPROLIDE ACETATE [USP-RS]
Common Name English
LEUPLIN
Brand Name English
PROSTAP
Brand Name English
LEUPROLIDE MONOACETATE
MI  
Common Name English
LEUPROLIDE ACETATE [USP MONOGRAPH]
Common Name English
ELIGARD
Brand Name English
LEUPRORELIN ACETATE [MART.]
Common Name English
FENSOLVI
Brand Name English
LUTEINIZING HORMONE-RELEASING FACTOR, 6-D-LEUCINE-9-(N-ETHYL-L-PROLINAMIDE)-10-DEGLYCINAMIDE ACETATE (SALT)
Systematic Name English
ENANTONE
Brand Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/16/1821
Created by admin on Sat Dec 16 05:01:05 GMT 2023 , Edited by admin on Sat Dec 16 05:01:05 GMT 2023
FDA ORPHAN DRUG 28688
Created by admin on Sat Dec 16 05:01:05 GMT 2023 , Edited by admin on Sat Dec 16 05:01:05 GMT 2023
NCI_THESAURUS C1910
Created by admin on Sat Dec 16 05:01:05 GMT 2023 , Edited by admin on Sat Dec 16 05:01:05 GMT 2023
Code System Code Type Description
RXCUI
203217
Created by admin on Sat Dec 16 05:01:05 GMT 2023 , Edited by admin on Sat Dec 16 05:01:05 GMT 2023
PRIMARY RxNorm
ChEMBL
CHEMBL1201199
Created by admin on Sat Dec 16 05:01:05 GMT 2023 , Edited by admin on Sat Dec 16 05:01:05 GMT 2023
PRIMARY
FDA UNII
37JNS02E7V
Created by admin on Sat Dec 16 05:01:05 GMT 2023 , Edited by admin on Sat Dec 16 05:01:05 GMT 2023
PRIMARY
EVMPD
SUB02900MIG
Created by admin on Sat Dec 16 05:01:05 GMT 2023 , Edited by admin on Sat Dec 16 05:01:05 GMT 2023
PRIMARY
DRUG BANK
DBSALT000105
Created by admin on Sat Dec 16 05:01:05 GMT 2023 , Edited by admin on Sat Dec 16 05:01:05 GMT 2023
PRIMARY
MERCK INDEX
m6779
Created by admin on Sat Dec 16 05:01:05 GMT 2023 , Edited by admin on Sat Dec 16 05:01:05 GMT 2023
PRIMARY Merck Index
NCI_THESAURUS
C1319
Created by admin on Sat Dec 16 05:01:05 GMT 2023 , Edited by admin on Sat Dec 16 05:01:05 GMT 2023
PRIMARY
SMS_ID
100000091573
Created by admin on Sat Dec 16 05:01:05 GMT 2023 , Edited by admin on Sat Dec 16 05:01:05 GMT 2023
PRIMARY
CAS
88793-81-1
Created by admin on Sat Dec 16 05:01:05 GMT 2023 , Edited by admin on Sat Dec 16 05:01:05 GMT 2023
NON-SPECIFIC STOICHIOMETRY
EPA CompTox
DTXSID7049009
Created by admin on Sat Dec 16 05:01:05 GMT 2023 , Edited by admin on Sat Dec 16 05:01:05 GMT 2023
PRIMARY
DAILYMED
37JNS02E7V
Created by admin on Sat Dec 16 05:01:05 GMT 2023 , Edited by admin on Sat Dec 16 05:01:05 GMT 2023
PRIMARY
PUBCHEM
657180
Created by admin on Sat Dec 16 05:01:05 GMT 2023 , Edited by admin on Sat Dec 16 05:01:05 GMT 2023
PRIMARY
CHEBI
63597
Created by admin on Sat Dec 16 05:01:05 GMT 2023 , Edited by admin on Sat Dec 16 05:01:05 GMT 2023
PRIMARY
CAS
74381-53-6
Created by admin on Sat Dec 16 05:01:05 GMT 2023 , Edited by admin on Sat Dec 16 05:01:05 GMT 2023
PRIMARY
RS_ITEM_NUM
1358503
Created by admin on Sat Dec 16 05:01:05 GMT 2023 , Edited by admin on Sat Dec 16 05:01:05 GMT 2023
PRIMARY